Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 2, 2005, Pages 189-194

  Mirochnick, Mark ^a,h   Stek, Alice ^b   Acevedo, Midnela ^c   Keller, Margaret ^d   Holland, Diane ^e   Capparelli, Edmund ^e   Connor, James ^e   Huang, Sharon ^f   Hughes, Michael ^f   Watts, Heather ^g   Mofenson, Lynne ^g   Bryson, Yvonne ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Obstetrics and Gynecology   (United States)

^c San Juan City Hospital   (Puerto Rico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f AIDS   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h BOSTON MEDICAL CENTER   (United States)

Author keywords

HIV; Nelfinavir; Neonate; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; HYDROXYL TERT BUTYLAMIDE; LAMIVUDINE; NELFINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACNE; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRONCHIOLITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVERGENT STRABISMUS; DIAPER DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ECZEMA; EYE DISEASE; GASTROINTESTINAL DISEASE; GRANULOMA; HEART DISEASE; HUMAN; INFANT; INFECTION; INTRAUTERINE GROWTH RETARDATION; LACRIMAL DUCT OCCLUSION; LOW BIRTH WEIGHT; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; NEUTROPENIA; NOSE DISEASE; OTITIS MEDIA; PERINATAL PERIOD; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; RASH; RECURRENT DISEASE; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SEBORRHEA CAPITIS; SEBORRHEIC DERMATITIS; SEPSIS; SINUS ARRHYTHMIA; SKIN DISEASE; SMALL FOR DATE INFANT; TACHYPNEA; THROAT DISEASE; THRUSH; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; WITHDRAWAL SYNDROME;

COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; GESTATIONAL AGE; HIV PROTEASE INHIBITORS; HUMANS; INFANT, NEWBORN; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 21144440967     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dunn DT, Brandt CD, Kirvine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995; 9(Suppl):F7-F11.
2. US Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://AIDSinfo.nih.gov. Accessed January 10, 2004.
3. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Performance of rapid HIV-1 testing at labor and delivery: a multicenter study [abstract 95]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
4. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-1414.
5. Shaffer N, Bulterys M, Simonds RJ. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1042-1043.
6. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362:1171-1177.
7. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1 infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118.
8. Viracept package insert. La Jolla, CA: Agouron Pharmaceuticals; 2001.
9. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J. 2001;20:746-751.
10. Brundage RC, Fletcher CX Fenton T, et al. Efavirenz (EFV) and nelfinavir (NFV) pharmacokinetics (PK) in HIV-infected children under 2 years of age [abstract 719]. Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco.
11. Litauen C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2003;22:48-55.
12. Rongkavilit C, van Heeswijk RP, Limpongsanurak S, et al. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Syndr. 2002;29:455-463.
13. Wu EY, Wilkinson JM II, Naret DG, et al. High-performance liquid Chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl. 1997;695:373-380.
14. Starr SE, Fletcher CV, Spector SA, et al. PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;7:659-663.
15. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;25:1874-1881.
16. Gatti G, Castelli-Gattinara G, Cruciani M, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2003;36:1476-1482.
17. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther. 2003;8:215-222.
18. Floren LC, Wiznia A, Hayashi S, et al. Pediatric AIDS Clinical Trials Group 377 Protocol Team. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003;112(Suppl):e220-e227.
19. van Rossum AM, Geelen SP, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:1008-1016.
20. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy; pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-1339.
21. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.
22. Gatti G, Castelli-Gattinara G, Cruciani M, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2003;36:1476-1482.
23. van Rossum AM, Bergshoeff AS, Fraaij PL, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:743-747.
24. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs. 2000;59:581-620.
25. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother. 2001;45:1086-1093.
26. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate [abstract 3035]. Presented at: 12th American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 1998; San Francisco.
27. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001;15:991-998.
28. Treluyer JM, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics, 1997;7:441-452.
29. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247:625-634.